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One of the major drawbacks found in most bone tissue engineering approaches developed so far consists in the
lack of strategies to promote vascularisation. Some studies have addressed different issues that may enhance
vascularisation in tissue engineered constructs, most of them involving the use of growth factors (GFs) that are
involved in the restitution of the vascularity in a damaged zone. The use of sustained delivery systems might also
play an important role in the re-establishment of angiogenesis. In this study, κ-carrageenan, a naturally occurring
polymer, was used to develop hydrogel beads with the ability to incorporate GFs with the purpose of establishing
an effective angiogenesis mechanism. Some processing parameters were studied and their influence on the final
bead properties was evaluated. Platelet derived growth factor (PDGF-BB) was selected as the angiogenic factor
to incorporate in the developed beads, and the results demonstrate the achievement of an efficient encapsulation
and controlled release profile matching those usually required for the development of a fully functional vascular
network. In general, the obtained results demonstrate the potential of these systems for bone tissue engineering
applications.
1. Introduction
Tissue engineering offers considerable promise in the repair
and replacement of diseased or damaged tissue and is being
explored as a potential alternative strategy for tissue repair and
organ replacement.1 One of most common studied approaches
for the development of tissue engineered substitutes aimed at
the regeneration of bone defects is based on the interaction of
three key elements, namely, a scaffold to support cells and tissue
growth, a reliable cell source, and bioactive factors, that can
enhance cells/tissue response in different ways.2-4
Besides the obvious demands of biocompatibility and con-
trolled degradation profile, the scaffold should feature some
important and challenging characteristics, such as to enable the
vascularization of the construct upon implantation.5-7 This is
critical for the cells survival and, therefore, for the formation
of the neo-tissues toward the implant. An adequate porosity is
required to allow the vascular ingrowth into the scaffolds to
improve the nutrients and oxygen supply to the cells in the
interior of the construct.8-13 The incorporation of bioactive
factors capable of promoting angiogenesis into the polymer
scaffold (directly or with carriers) leads to an accelerated and
successful tissue growth/regeneration.12-15 In this context, the
design of scaffolds, based on biodegradable polymeric controlled
release system constitutes a potential strategy to obtain tissue
engineering constructs with increased complexity and function-
ality.7
The selection of a suitable material and format for the
development of a drug delivery system to be used in tissue
engineering applications is a difficult task.16 A variety of both
synthetic and natural polymers have been extensively studied
as base materials for obtaining bioactive molecules carriers.17,18
To achieve a successful release of growth factors in a tissue
engineering approach, one must consider a number of para-
meters:10,19-21 (i) the released growth factors must target the
desired cell population; (ii) once they are released, they
experience extremely short plasma circulation times and rapid
renal clearance; (iii) in general, tissues should be exposed for
relatively long periods to these molecules to obtain the proposed
effect.15,19,22 In summary, a spatiotemporal controlled release
system for delivery of growth factors is recommended.4,19
Nevertheless, developing an encapsulated protein formulation
has been a difficult process because proteins lose their stability
quite easily during the processing of the carrier.23,24 In this
context, hydrogels have emerged as relevant protein carrier
systems because they can offer mild processing conditions and
hydrophilic environment to the encapsulated protein, therefore,
decreasing their potential denaturation and aggregation.25
Synthetic polymers, known for their processability have been
applied in this field of research, especially saturated poly-R-
hydroxy esters, including poly(lactic acid) (PLA) and poly-
(glycolic acid) (PGA).6,26 However, many complications have
been associated to these polymers from the creation of an acidic
environment upon degradation, a feature that is clearly inap-
propriate for a protein-delivery strategy.27 On the other hand,
natural polymers have been attractive for this field because they
present better biological responses besides a closest-mimicking
strategy for a tissue replacement. Some polysaccharides includ-
ing starch, alginate, hyaluronic acid, and chitosan have been
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used for the development of porous scaffolds and hydrogels
for protein and cell encapsulation.6
Carrageenan, a naturally occurring polysaccharide shows
interesting properties for the development of a controlled release
strategy, mainly due to its gelling abilities. Their linear primary
structure is based on alternating copolymers of 1,3-linked !-D-
galactose and 1,4-linked R-D-galactose, with varying degrees
of sulfatation. The units are joined by alternating R-1,3 and !-1,4
glycosidic linkages forming the disaccharide repeating unit of
carrageenans.28-30 Due to their half-ester sulfate moieties,
carrageenans are strongly anionic polymers. The most common
types of carrageenan are traditionally labeled kappa (κ), iota
(γ), and lambda (λ).31 The structures of the three main forms
of carrageenan differ only in the number of sulfate groups per
disaccharide: κ has one, γ has two, and λ has three.32,33
Carrageenan has been increasingly used in the cosmetic and
pharmaceutical industries.28 The carrageenan biocompatibility
has also been discussed in several studies and when used in
adequate concentrations, it does not induce a toxic reaction.34
Upon cooling under appropriate salt conditions, both γ- and
κ-types undergo coil-helix conformational transitions which
may lead to gelation, developing ionotropic and thermotropic
gels.35 Gelation of γ-carrageenan is enhanced mainly by calcium
and κ-carrageenan by potassium ions. γ-Carrageenan is either
hot or cold soluble and forms soft elastic gels, while the κ-type
dissolves only when heated and forms strong gels that tend to
be firm and brittle.32,36,37
According to the above-described gelation properties of the
main types of carrageenan, it is presumed that the κ-form could
be the most appropriate type to be applied in the development
of new carrier formulations, to be integrated in a global tissue
engineering strategy to promote bone regeneration.
The entrapment of proteins in an ionotropically cross-linked
biodegradable hydrogels may improve the stability of the protein
and make it less prone to interference of various formulation
excipients.22,38
Platelet derived growth factor (PDGF) exists in five isoforms
and plays an important role in the stimulation of angiogenesis
in vivo. Although it does not directly stimulate endothelial cell
proliferation, it acts as a potent mitogen for smooth muscle cells
(SMCs) and fibroblasts, stimulating SMCs to produce direct
angiogenic factors like vascular endothelial growth factor
(VEGF) and basic fibroblast growth factor (bFGF). It is also
thought to recruit pericytes and induce the differentiation of
endothelial precursor cells.11,24,39-42 Besides that, PDGF exerts
one of the strongest chemotactic effects on osteoblasts and stem
cell precursors.43-45 The PDGF-BB isoform is one of the most
active in these physiological events; therefore, its choice for
encapsulation within the developed hydrogel.
We hypothesized that carrageenans constitute a versatile
system in the development of new formulations for the loading
and release of different types of protein-based agents as different
types of this polysaccharide may be combined. This could be
used to adjust the cross-linking density and the charge of the
gels to control the release profile of the entrapped bioactive
agent.
2. Materials and Methods
In this work it is proposed the design of a biodegradable polymeric
carrier system based on carrageenan for the sustained delivery of
bioactive factors, to promote angiogenesis in a tissue engineering
approach. For that, the release profile of PDGF-BB encapsulated in
κ-carrageenan beads was evaluated and some other parameters such as
encapsulation efficiency, protein distribution, and cytotoxic evaluation
were performed.
2.1. Beads Preparation. Concentrated κ-carrageenan (22048, Sigma-
Aldrich) solutions in distilled water were prepared by heating the
dispersion at 60 °C with constant stirring to obtain homogeneous
solutions (1.5 and 2% (w/v)). The beads were prepared using an
ionotropic gelation method. Briefly, 5 mL of the previously heated
carrageenan solution were extruded dropwise through a syringe needle
(0.8 mm in diameter) using a pump (AL-1000, Alladin Programmable
Syringe Pump), into 40 mL of a KCl (131494.1211, Panreac) solution.
Two batches of the resulting beads were allowed to harden for defined
periods in the cross-linking solution, while a third batch was removed
after a short period. The gel beads were filtered, washed with distilled
water twice, and dried in an oven at 37 °C until constant weight is
achieved. Different types of processing parameters were varied, namely,
the polysaccharide concentration (1.5% or 2% (w/v)), the KCl
concentration of the precipitation bath (1% or 5% (w/v)), and the
hardening time in this solution (∼2, 15, and 60 min).
2.2. Characterization of the Developed Beads. To evaluate the
potential of the developed κ-carrageenan beads and establish the
formulation/conditions that lead to the systems with the most promising
properties for the desired application, the systems were extensively
characterized by analyzing their morphology, water uptake, and
mechanical stability.
2.2.1. Beads Morphological Characterization. The surface morphol-
ogy of beads was visualized by stereomicroscope (Zeiss - Stemi 2000-C
KL 1500 LCD, 459315) and environmental scanning electron micros-
copy (ESEM-EDS, FEI Quanta 400, U.K.). For ESEM analysis, the
samples were evaluated in their swollen form under 12 mBar of
pressure. The internal structure was assessed by cryogenic scanning
electron microscopy (JEOL JSM 6301F equipped with a Gatan Alto
2500 EDS).
2.2.2. Mechanical Stability. A determined amount of beads (10
beads/well) were suspended in 1 mL of PBS solution (pH 7.4) with
0.02% (w/v) sodium azide in a six-well culture plate. The plate was
placed on a thermostatic water bath, at 150 rpm and 37 °C. After 1, 2,
6, 24, 48, and 168 h, the beads were collected and observed under a
stereomicroscope to count the disrupted beads.
2.2.3. Water Uptake. The swelling ability of the κ-carrageenan beads
was determined by accurately weighing an amount of dry beads and
then suspending them in 5 mL of PBS, pH 7.4, containing 0.02%
(w/v) sodium azide at 37 °C. After predetermined intervals, the beads
were collected by filtration, the excess water was blotted from the
surface with filter paper, and the particles were weighed immediately.
Eq 1 was used to determine the swelling degree
%water uptake )
(mi - m0)
m0
× 100 (1)
where mi is the mass of the swollen beads and m0 is the initial mass of
the original dry beads.
2.3. Loading of the Model Protein (OVA) and the Growth
Factor (PDGF-BB). The incorporation of protein molecules into the
beads was performed and the efficiency of encapsulation was evaluated.
Albumin from chicken egg white (OVA) (A5503-5G, Sigma, molecular
weight 42.7 KDa, pI 4.54) was selected as the model protein for these
studies because its molecular weight is within the same range as the
growth factors’.
2.3.1. Encapsulation Efficiency. For the preparation of protein-loaded
κ-carrageenan beads, different formulations with distinct theoretical
protein loadings of model protein OVA, and PDGF-BB (100-14B,
PeproTech, molecular weight 24.3 KDa, pI 10.1) were prepared. The
protein solution was mixed with the κ-carrageenan solution in order to
obtain a homogeneous distribution and the following procedure was
the same as described in section 2.1.
For the model protein, the OVA theoretical loadings were 5 and
10% (w/w) with respect to the weight of κ-carrageenan for each
formulation. In the case of the growth factor, the theoretical loading
referred to the weight of carrageenan was 0.01%.
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Encapsulation efficiency was determined by an indirect procedure.
After the beads preparation process, they were separated from the
suspension medium by filtration and the aqueous phase was collected
to quantify the protein content in this solution. The nonloaded free
protein was determined by the micro-BCA (23235, Pierce) and ELISA
(900-K04, PeproTech) kit assays for OVA and PDGF-BB quantification,
respectively. Absorbances were measured in a microplate reader,
according to each protocol. A calibration curve was made using the
supernatant of blank beads. Encapsulation efficiency is calculated by
eq 2
%encapsulation efficiency )
(mpt - mps)
mpt
× 100 (2)
where mpt corresponds to the initially encapsulated mass of protein,
mps is the mass of protein in the KCl solution.
2.3.2. Fourier Transform Infrared Spectroscopy. Fourier transform
infrared spectroscopy (IR-Prestige-21, FTIR Shimadzu) was used to
record the infrared spectra of κ-carrageenan, OVA, empty κ-carrageenan
beads, κ-carrageenan beads encapsulating OVA, and physical mixture
of polymer and protein using KBr pellets. The frequency range covered
was 400-4400 cm-1 with a minimum of 36 scans and a resolution of
4.0 cm-1.
2.3.3. Protein Distribution. For visualizing the protein distribution
in the beads, OVA was labeled with fluorescein isothiocyanate (FITC;
46951, Sigma). Briefly, the OVA solution was prepared by dissolving
the protein in sodium carbonate buffer (S4132-500G, Sigma), 0.1 M,
pH 9, at a concentration of 10 mg/mL. FITC was dissolved in anhydrous
dimethyl sulfoxide (DMSO; 34943, Riedel de Hae¨n) at the same
concentration in a darkened laboratory, by simply mixing with vortex.
Then the FITC solution was slowly added to the protein solution, at a
final ratio of 0.015 mg FITC/mg protein under continuous and moderate
agitation at room temperature. The mixture was then allowed to react
for 8 h at 4 °C in the dark under continuous shaking. The solution was
then transferred to a preswollen dialysis membrane tube and after several
exchanges of PBS, the dialyzed protein solution was lyophilized. The
obtained FITC-labeled OVA was incorporated into the κ-carrageenan
beads by the procedure described in sections 2.1 and 2.3.1. The protein
distribution in the beads was examined by fluorescence stereomicros-
copy (Olympus SZX16).
2.3.4. In Vitro OVA and PDGF-BB Release Studies. Approximately
100 mg of the dried beads encapsulating OVA and PDGF-BB were
suspended in a glass apparatus with 5 mL of PBS, pH 7.4, containing
0.02% (w/v) sodium azide as bacteriostatic agent. The vials containing
the bead suspensions were kept at 37 °C in a shaking water bath at
150 rpm. At predetermined intervals, aliquots (1 mL) of the supernatant
were withdrawn and frozen at -20 °C for further protein quantification
and were replaced with an equal volume of fresh buffer solution to
maintain the total volume constant during the release profile study. The
supernatant was used to determine the amount of the released protein.
The protein quantifications were performed using the micro-BCA assay
kit and ELISA for OVA and PDGF-BB determinations, respectively.
The weight of the beads was selected to give a final protein
concentration of less than 10% of the saturation concentration in the
medium to ensure sink conditions, which were maintained throughout
the whole study.
2.3.5. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophore-
sis (SDS-PAGE). SDS-PAGE of the released model protein was
performed using a 10% acrylamide resolving gel, to evaluate protein
molecular weight after the encapsulation and release process (each run
contained 15 µL of the initial mixture: 15 µL of OVA 1 mg/mL and 8
µL of SDS buffer). The samples were heated at 95 °C for 7 min. The
gel was stained with copper coloration (15 min in a 0.3 M CuCl2
solution).
2.4. Cytotoxicity Evaluation. To assess the carriers’ cytotoxicity,
one formulation was chosen: 2% (w/v) κ-carrageenan precipitated in
5% KCl hardened for 60 min. This was the tested condition because it
showed adequate morphological features and protein release profiles
matching the goal of the study. For the biological tests, the carrageenan
solution was sterilized at high temperatures prior to the beads
preparation.
The cytotoxicity tests were performed according to ISO/EN 109935
guidelines.46 For the extract preparation, an amount of 100 beads were
incubated in 15 mL (according to the surface area/volume ratio
established in the referred guidelines) of culture medium for 24 h at
37 °C with constant shaking (60 rpm). As negative control for
cytotoxicity behavior, latex extracts were used, prepared in the same
conditions as described for the test samples. All the extracts were filtered
(using a syringe filter of 0.45 µm pore size) to eliminate the possible
presence of solid particles of the material.
The cells used in this study were an immortalized cell line of
subcutaneous areolar fibroblasts from mouse origin purchased from
Collection of Cell Culture (ECACC, U.K.; ref 85011425), designated
L929. These cultured cells were tripsinized, resuspended in culture
medium at a density of 2 × 104 cells/mL and plated (200 µL/well) in
96-well plates at 4 × 103 cells/well. The plates were incubated for
24 h at 37 °C in a 5% CO2 humidified incubator. After that, the medium
was replaced by the prepared extracts, using culture medium by itself
as positive control, and cultured for 1, 3, 7, and 10 days. At each time
point, the culture medium was replaced by MTS solution, 300 µL/well
(Promega), and incubated for 3 h at 37 °C in a 5% CO2 humidified
incubator. MTS solution was transferred to new 96-well plate and
absorbance read at 490 nm. All materials were tested in six replicates
for each extract for three independent experiments.
2.5. Statistical Analysis. All the experiments were performed with
at least three replicates. Results are expressed as mean ( standard
deviation. Differences between the experimental results were analyzed
according to a Student t-test, with the limit for statistical significance
being defined as p < 0.01.
3. Results and Discussion
3.1. K-Carrageenan Beads Preparation and Characteriza-
tion. It was possible to obtain beads using all the described
formulations. The obtained beads exhibit a smooth surface and
a homogeneous spherical shape with their dimensions ranging
between 1 and 2 mm, as it was possible to observe using
stereomicroscopy (Figure 1a) and ESEM (Figure 1b). Neverthe-
less, some of the beads presented lateral rugosity. The spherical
shape of the hydrated ones was usually kept after the drying
process, especially for the highly cross-linked beads.
CryoSEM allows the investigation of the morphology of
hydrated samples preventing the modification of its internal
structure. One of the CryoSEM fractures performed on the 2%
κ-carrageenan beads, precipitated in 5% KCl for 15 min, is
displayed in Figure 2a, revealing significant differences between
the morphology of the beads’ surface and their internal structure.
In fact, it can be observed an increase in the porosity from the
Figure 1. Microscopic images of representative batches of κ-carra-
geenan beads obtained by the formulation: 2% (w/v) κ-carrageenan
precipitated in 5% (w/v) KCl and hardened for 15 min. (a) Stereomi-
croscopy image of representative beads. The particles present a
spherical shape and homogeneous dimensions. (b) Environmental
scanning electronic microscopy image of the beads’ smooth surface
morphology.
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right to the left side of the image, that is, from the surface to
the interior of the bead. Therefore, the inner areas of the bead
show a more disorganized structure and interconnected porosity,
with pores with sizes between 1 and 2 µm. However, a
nanostructure phase exhibiting a fibrilar texture may be seen in
the interior of such voids (Figure 2b).
The increase in porosity from the surface to the inner core
of the beads results from a higher degree of cross-linking in
the outer layers of the beads. When the κ-carrageenan solution
drops from the syringe to the hardening solution, instantaneous
interfacial cross-linking takes place followed by a more gradual
gelation of the interior.
In addition, the influence of some parameters such as
κ-carrageenan concentration, KCl solution concentration, and
hardening time on the structure of the obtained κ-carrageenan
beads was evaluated. In general, it was found from macroscopic
observations that the increase in the κ-carrageenan concentration,
KCl solution concentration, and hardening time improved the
long-term maintenance of the spherical shape of the beads.
Although the beads prepared from the 2% (w/v) κ-carrageenan
concentrations seemed to be stronger than the others, when the
mechanical stability assessment was performed, no differences
were observed. In fact, all the formulations were resistant to
the agitation and only after 1 week of constant shaking it was
observed that the beads started to shrink. Both 1.5 and 2%
(w/v) κ-carrageenan solutions were able to produce particles
when precipitated in 1 and 5% (w/v) KCl solutions (κ-
carrageenan concentrations under those values were not able
to produce beads that could sustain their shape). Even with only
a short cross-linking period, the particles remained morphologi-
cally stable, but some improvements were observed with the
increase in the hardening time in KCl solution. From the
different processing combinations analyzed, the conditions
corresponding to the precipitation of 1.5% κ-carrageenan in 1%
KCl with short hardening time were unable to produce spherical
beads. The lower carrageenan concentration and the reduced
cross-linking reaction (due to the short exposure of the beads
to a less concentrated KCl solution) are the main reasons for
the instability of this last formulation.
For the following characterization procedures, only the beads
prepared with a 2% (w/v) κ-carrageenan concentration were used
as they showed a more stable condition for further analysis and
application.
Water uptake is a determinant property for drug delivery
studies. In the case of hydrogels, swelling is the most important
mechanism to promote the release of the incorporated drug
because the penetration of water molecules into the structure
of the dry hydrogel promotes the relaxation of the chains and
the increase in the pores’ size. The swelling degree determines
the diffusivity of molecules within the hydrogel and it was
determined with PBS as the immersion solution, as this buffer
will also be used as the release medium in the following
experiments.47 The developed κ-carrageenan beads show an
affinity for water absorption that is explained by the presence
of highly polar sulfate groups in the polymer structure.37
From the water uptake measurements displayed in the Figure
3, it is possible to observe that a quick burst of water penetration
occurs within the first 8 h of testing. After this sharp increase,
the swelling increases in a more controlled manner.
One should expect that the cross-linking degree and polymer
concentration should affect the swelling based on their effects on
the gel charges and network density.48 Figure 3a and b shows that
the conditions prepared with a short cross-linking period (2 min)
present a higher water uptake percentage. The influence of the
hardening solution concentration is also visible as the beads
prepared with 5% KCl display a lower swelling when compared
to the hydrogels hardened in 1% KCl. In both situations, the cross-
linking degree affects the swelling rate in an inverse relationship:
as the former increases, the latter is reduced. Degradation studies
of the carrageenan beads were also performed (data not shown).
The beads were kept in PBS at a water bath programmed at 37 °C
and 60 rpm and it was possible to observe that, during the first
days of immersion in PBS, the hydrogels’ dry mass (after each
time point, the beads were dried at 37 °C until they achieved a
constant weight) decreased up to 30% of the initial dry mass. This
reduction can be attributed to the release of residual cross-linking
agent. After this decrease, the dry mass was stable up to 8 weeks,
thus showing the capability of the systems to be used for long-
term delivery purposes.
3.2. Incorporation and Release of the Model Protein in
the K-Carrageenan Beads. As previously mentioned, the incor-
poration of proteins into the beads was first carried out using OVA
as a protein model. The encapsulation technique that was used in
this study is a considerably fast, simple, and inexpensive method
for the entrapment of bioactive molecules. The encapsulation
efficiency (EE, %) obtained for the different prepared formulations
Figure 2. Cryo-SEM images of the surface fracture from beads prepared with 2% (w/v) κ-carrageenan in 5% (w/v) KCl for 15 min: (a) a cross-
linking density gradient is observed in the surface fracture of the bead (the arrow is directed from the surface to the inner core of the bead). The
network in the outer layers of the bead indicates a higher degree of cross-linking from the surface to the interior; (b) a magnified image of the
inner core of the bead. The hydrogel-like porosity dominates the structure.
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is shown in Figure 4. The results presented in this figure show
that all the conditions displayed an EE above 50%.
The nonloaded beads were similar in shape and morphology
to the protein-loaded beads. The parameter which seems to be
more influent over the encapsulation efficiency is the cross-
linking time. When carrageenan beads are developed with a 2
min hardening time, the encapsulation efficiency remains higher
than 80% and is significantly above all the other formulations
Figure 3. Water uptake studies for different formulations of 2% κ-carrageenan beads. (a) Hydrogels prepared with 1% KCl cross-linked for
different periods: [ cross-linking time (CT) ) 2 min with tendency curve (-), 0 CT ) 15 min with tendency curve (----), and ] CT ) 60 min with
tendency curve (- -); (b) hydrogels prepared with 5% KCl cross-linked for different periods: [ CT ) 2 min with tendency curve (-), 0 CT ) 15
min with tendency curve (----), and ] CT ) 60 min with tendency curve (- -). The effect of KCl concentration and immersion time in the cationic
solution on the swelling ability of the beads was evaluated.
Figure 4. OVA encapsulation efficiency studies for different formulations of 2% κ-carrageenan beads. CT, cross-linking time. The formulations showing
the symbol # present statistically significant differences relatively to all systems prepared with a 2 min cross-linking time (p < 0.01). 4 represents a
statistically significant difference (p < 0.01) relatively to both formulations: 2% κ-carrageenan + 0.1% OVA in 1% KCl for 60 and 15 min. $ represents
a statistically significant difference (p < 0.01) relative to both designs: 2% κ-carrageenan + 0.1% OVA in 5% KCl for 60 and 15 min. The symbol * is
used for individual specific significant differences (p < 0.01) between beads prepared with a reduced hardening time (CT ) 2 min).
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(symbol #). The protein release during the immersion period
justifies the above-mentioned difference as carrageenan sulfate
groups are interacting with the K+ ions present in the coagulation
bath. Independently of the KCl and protein concentrations, this
effect was observed.
In the formulations prepared with 0.1% OVA, significant
differences (symbol 4) are observed between the encapsulation
efficiency of particles produced in 1 and 5% KCl for the longest
cross-linking periods (15 and 60 min). Above a critical salt
concentration, the anionic carrageenan groups get saturated,
which causes a shift from polymer-solvent to polymer-polymer
interactions.49,50 The expected electrostatic interactions between
κ-carrageenan and the incorporated protein become less intense
due to the competition for the sulfate groups. This significant
difference is not pronounced in the conditions encapsulating
0.2% OVA as this concentration might be a threshold to elicit
the differences imposed by the different cross-linker bath
conditions. In general, with both OVA loadings (0.1 and 0.2%
(w/v)), the encapsulation efficiency is lower for the formulations
prepared in 5% KCl as the competition with the K+ ions for
the sulfate groups is enhanced. In these cases, a higher fraction
of the protein does not get fixed to the gel.
For all the formulations, there is no significance over the
encapsulation efficiency between conditions cross-linked for 15
and 60 min.
The FTIR spectra of the different samples were used to
identify the typical peaks and to observe if the protein was
effectively incorporated into the particulate systems. The FTIR
spectra from the different κ-carrageenan containing samples is
presented in Figure 5 and exhibits some identifiable vibrational
peaks: the broadband from 3150 to 3600 cm-1 correspond to
the hydroxyl group; the band from 2968 to 2850 cm-1 assigned
to the C-H stretch, the peak at 1640 cm-1 related to polymer-
bound water, the ester sulfate peak is seen at 1225 cm-1, the
peak at 930 cm-1 for 3,6-anhydro-D-galactose and the peak at
845 cm-1 for the D-galactose-4-sulfate.38 On the other hand,
the OVA spectrum also shows the usual protein peaks, including
one wide band between 3190 and 3400 cm-1 due to the N-H
stretch, one weak peak at 2980 cm-1 due to C-H stretch, peaks
at 1650 and 1560 cm-1 due to the amide bands I (representing
80% of the CdO stretching vibration of the amide group) and
II (mainly N-H bending), respectively. The empty beads
spectrum was similar to the protein-loaded one, which can be
explained by the incorporation of the protein into the carrag-
eenan matrix. The FTIR allows the detection of the established
bonds only few micrometers through the beads’ surface,
therefore, the similarities between both spectra prove the OVA
distribution mainly in the hydrogel’s core (which converges with
the encapsulation efficiency findings).51 In the physical mixture
of OVA and κ-carrageenan powder, it is possible to identify
peaks correspondent to both samples. These spectrum confirm
that the OVA is incorporated in the beads at a molecular level.
Figure 6 resumes the OVA release studies of different
formulations. The release profiles were mainly characterized by
a burst release within the first few hours of the study (Figure
6c,d). High release rates occur in the systems cross-linked in
KCl for a short period of time (2 min) due to the presence of
the drug at and near the surface. The less cross-linked hydrogels
also present higher-dimensioned porous structure, which allows
a quicker diffusion of the encapsulated molecules. The interac-
tion between the K+ in the coagulation bath and the sulfate
groups in the carrageenan structure creates a denser network
which is more effective in the entrapment of proteins within
the matrix.
However, the beads prepared from the 2% (w/v) κ-carrag-
eenan solution precipitated in 5% (w/v) KCl and hardened for
60 min showed a much more controlled release profile. Within
the first two days of release, while many other formulations
prepared with 5% KCl already had released all the protein
content, in this case only around 60 and 50% (for 0.2 and 0.1%
OVA initial loadings, respectively) were quantified in the release
medium, maintaining a slow yet controlled release profile during
the following days.
The displayed protein release profile from the κ-carrageenan
beads was typical of a hydrogel and the main mechanism
involved in this process is the swelling of the beads, which
promotes the polymer chain relaxation due to water penetration
into the matrix. High release rates take place due to the increased
mobility of the protein inside the matrix, allowing its diffusion
to the medium.52,53 In this particular case, the dissolution of
κ-carrageenan chains that were not cross-linked also seems to
contribute to the quick phase of the release profile. This burst
seems to be more prominent for the beads prepared with lower
cross-linking degrees; in this case, the particles are less dense
and the protein is less tight to the matrix. After the burst phase,
the release continues with a diffusion mechanism through the
matrix with a much slower release rate. In fact, in most of the
release profiles a stationary phase is visible, which is probably
due to the transition between the release of OVA disposed on
the surface of the beads and the release of the OVA that was
dispersed in the inner core of the carrier. Therefore, this release
profile can be correlated with the beads’ structure (shown in
Figure 2). The protein content that was dispersed near the surface
Figure 5. FTIR spectra. Transmittance is shown in arbitrary units (AU)
as the analysis is qualitative: (a) κ-carrageenan powder; (b) κ-carra-
geenan blank beads; (c) κ-carrageenan beads encapsulating OVA;
(d) physical mixture of blank beads and OVA; (e) OVA.
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in the denser network was initially released to the medium while
the OVA distributed in the core of the bead migrated to the
outer layers being released afterward. The controlled profile
obtained for the beads cross-linked for 1 h suggests that an
increase of the hardening time might play a key role in the
development of a sustained delivery.
The protein loading also seems to affect the release pace as
the highest loading formulations (0.2% OVA) showed quicker
Figure 6. OVA release profiles from carrageenan beads. (a) Formulations represented by the symbols: [ 2% κ-carrageenan + 0.2% OVA in
1% KCl 60 min; 9 2% κ-carrageenan + 0.2% OVA in 1% KCl 15 min; 2 2% κ-carrageenan + 0.2% OVA in 1% KCl 2 min; ) 2% κ-carrageenan
+ 0.1% OVA in 1% KCl 60 min; 0 2% κ-carrageenan + 0.1% OVA in 1% KCl 15 min; 4 2% κ-carrageenan + 0.1% OVA in 1% KCl 2 min. (b)
The symbols represent the same formulations described in (a) but all disposed prepared in 5% KCl, all disposed in the same order. (c) OVA
release up to 6 h for the formulations described in (a). (d) OVA release up to 6 h for the formulations described in (b).
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delivery profiles in the conditions prepared with a high cross-
linking time (60 min). This effect might be explained by the
increased protein gradient toward the release media because the
beads encapsulate a higher amount of OVA.
SDS-PAGE analysis (Figure 7) was performed to evaluate
the molecular weight of the released protein. After 2 days of
delivery, the standard OVA run in the electrophoresis gel is
quite similar to the encapsulated one.
The protein distribution was evaluated by fluorescence
stereomicroscopy, using the beads corresponding to the follow-
ing formulation: 2% κ-carrageenan + 0.2% OVA-FITC pre-
cipitated in 5% KCl for 1 h. OVA-FITC was found to be
homogeneously distributed on the beads surface (Figure 8a).
However, after a 2 day period release, the fluorescence was
reduced (Figure 8b), which demonstrates the protein diffusion
toward the outer surface of the matrix.
3.3. Incorporation and Release of the Growth Factor
in the K-Carrageenan Beads. The results obtained from the
release studies with the model protein, OVA, suggested that by
changing some processing parameters one could obtain different
sustained delivery profiles of the molecules; this information
can be useful in the development of adequate formulations for
the controlled release of growth factors in tissue engineering
strategies. However, the release behavior is also influenced by
the encapsulated protein, and because of that, the previous
conclusions cannot be directly applied to other proteins without
testing the system with the desired growth factor. In the proposed
system, the penetration of K+ ions through the κ-carrageenan
network and the establishment of ionic bonds between the
cations and the sulfate groups strengthen the gel, which might
be important for the promotion of a slower release. Simulta-
neously, this effect is responsible for the reduction of encapsula-
tion efficiency, which is a negative feature for yield and
economic aspects. Therefore, it is important to find a compro-
mise between an adequate release profile and an advantageous
entrapment efficiency, which should be designed according to
the target application of the system.
The formulation chosen for PDGF-BB encapsulation and
release studies was 2% κ-carrageenan in 5% KCl 60 min because
its OVA release profile matches the desired one.
The initial content of PDGF-BB was 0.01% (w/w) to
κ-carrageenan weight. With the incorporation of PDGF-BB into
the κ-carrageenan matrix, the encapsulation efficiency still
remains quite high. The incorporation of PDGF-BB into the
carrageenan matrix proved to be quite successful as 74.04 (
2.77% of the initial growth factor was encapsulated. This value
is higher than the ones with this formulation for the model
protein and might be related to the weaker competition between
K+ ions and the protein. Moreover, the initial protein loading,
lower in the PDGF-BB case, might also contribute to a reduction
in the establishment of a diffusion gradient toward the release
media.
Once again, the results displayed on Figure 9 show that the
release profiles correspond typically to a two step process, in
which the first correspond to a burst release that takes place
within the first 4 days. The PDGF-BB release from the
κ-carrageenan carriers is apparently slower than the OVA
release. The growth factor delivery lasted for all the test period,
releasing close to 25% of the initial protein content within the
first 2 weeks, thus, showing a controlled delivery process. The
release of PDGF-BB followed a discrete initial burst release,
thus, avoiding the more pronounced burst diffusion observed
in several other published systems.54-59
In this work, the protein is not chemically attached to the
polymer. The interactions that occur between the molecules
are only electrostatic and hydrophobic. The results suggest that
the interactions of PDGF-BB with the carrageenan matrix are
stronger than those observed for the case of OVA. The higher
isolectric point (pI) of PDGF-BB compared with OVA’s is one
of the reasons for this difference as the higher resultant
electrostatic interactions produced between the κ-carrageenan
molecule and the protein can be responsible for a stronger
attachment to the gel structure.
An initial faster growth factor release can be advantageous
in some applications as it rapidly stimulates the beginning of
relevant biological processes, which are maintained during the
slower release phase that usually follows this initial burst. In
Figure 7. SDS-PAGE of OVA protein: (a) standard OVA, with initial
concentration of 1 mg/mL; (b) OVA released from the formulation:
2% (w/v) κ-carrageenan + 0.2% OVA precipitated in 5% KCl and
hardened for 2 min in that solution. The sample was taken after 2
days of release, when the release had already finished; (c) Marker
standard having the indicated molecular masses in KDa.
Figure 8. Fluorescence stereomicroscopy images of 2% κ-carrag-
eenan + 0.2% OVA-FITC in 5% KCl 60 min beads: (a) κ-carrageenan
bead right before the release study initiation; (b) κ-carrageenan bead
after 2 days of release studies.
Figure 9. PDGF-BB release from 2% κ-carrageenan beads cross-
linked in 5% KCl for 60 min.
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several published studies,15,21,40,60-62 a continuous 2-4 week
growth factor release is claimed to be the desirable profile, but
many other problems are attained in these studies, namely, the
bioactivity of the encapsulated bioactive factor during the release
study. In this case, the time scale of the release was achieved
and after 2 weeks there is still a relevant amount of growth
factor entrapped within the carrier matrix, available for release
in a latter phase of the study. PDGF-BB is required for the
maturation of newly formed blood vessels during the neo-
vascularization process, therefore, this delivery system seems
appropriate for this goal.
3.4. Cytotoxicity Assessment. The results obtained from the
cytotoxicity (cell viability) assay performed, namely, the MTS
test, revealed that the extracts of the tested condition did not
affect the viability of the cell line L929 (Figure 10). It is possible
to observe that the number of viable cells was similar to the
cell number obtained in the positive control. By day 10, cell
viability decreases, but this is easily explained by to the cell
death induced by space limitations of culture area.
4. Conclusions
This study demonstrated that κ-carrageenan can be an
adequate option for the development of carrier systems to
encapsulate growth factors or other bioactive agents of relevance
in tissue engineering applications, avoiding the use of organic
solvents. The high encapsulation efficiency and the controlled
delivery profile showed that, with the proper parameters
formulation, it is possible to achieve a sustained release of the
incorporated bioactive factor. Further cellular studies will be
performed to evaluate the biological activity of the released
PDGF-BB.
The release profile can be tailored by varying several
processing conditions. Moreover, it is expected that the proper-
ties of the hydrogels can also be varied by combining different
types of carrageenans and by compounding them with other
polysaccharides. The release kinetics displayed with these
hydrogel beads might be used as a control for other hydrogel
shapes. The thermogelling properties of such materials may also
be used in new injectable systems that could be used to deliver
growth factors and even cells through minimally invasive
procedures.
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